PremiumThe FlyVigil Neuroscience price target lowered to $13 from $24 at Wedbush Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution Promising Clinical Progress and Strategic Advancements Justify Buy Rating for Vigil Neuroscience PremiumCompany AnnouncementsVigil Neuroscience Announces Positive Phase 1 Trial Results Vigil Neuroscience reports data from Phase 1 trial on VG-3927 Vigil Neuroscience initiated with an Outperform at William Blair PremiumCompany AnnouncementsVigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data Vigil Neuroscience announces FDA removed partial clinical hold on VG-3927 Vigil Neuroscience price target lowered to $16 from $17 at Guggenheim 
